Eccrine sweat glands, which are distributed over the whole bodies of primates and humans, have long been regarded mainly to have a function in thermoregulation. However, the discovery of dermcidin-derived antimicrobial peptides in eccrine sweat demonstrated that sweat actively participates in the constitutive innate immune defense of human skin against infection. In the meantime, a number of studies proved the importance of dermcidin in skin host defense. Several reports also state that peptides processed from the dermcidin precursor protein exhibit a range of other biological functions in neuronal and cancer cells. This review summarizes the evidence gathered until now concerning the expression of dermcidin and the functional relevance of dermcidin-derived peptides.

Keywords:
Antimicrobial peptides, Dermcidin, Host defense, Skin innate immune response
1.
Schittek B, Paulmann M, Senyurek I, Steffen H: The role of antimicrobial peptides in human skin and in skin infectious diseases. Infect Disord Drug Targets 2008;8:135–143.
2.
Wiesner J, Vilcinskas A: Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010;1:440–464.
3.
Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, Schirle M, Schroeder K, Blin N, Meier F, Rassner G, Garbe C: Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2001;2:1133–1137.
4.
Rieg S, Seeber S, Steffen H, Humeny A, Kalbacher H, Stevanovic S, Kimura A, Garbe C, Schittek B: Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites. J Invest Dermatol 2006;126:354–365.
5.
Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL: Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002;119:1090–1095.
6.
Park JH, Park GT, Cho IH, Sim SM, Yang JM, Lee DY: An antimicrobial protein, lactoferrin exists in the sweat: proteomic analysis of sweat. Exp Dermatol 2011;20:369–371.
7.
Folk GE Jr, Semken HA Jr: The evolution of sweat glands. Int J Biometeorol 1991;35:180–186.
8.
Wilke K, Martin A, Terstegen L, Biel SS: A short history of sweat gland biology. Int J Cosmet Sci 2007;29:169–179.
9.
Lupi O: Paleodermatology. Int J Dermatol 2008;47:9–12.
10.
Lupi O: Ancient adaptations of human skin: why do we retain sebaceous and apocrine glands? Int J Dermatol 2008;47:651–654.
11.
Elizondo RS: Primate models to study eccrine sweating. Am J Primatol 1988:265–276.
12.
Deans DA, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KC, Ross JA: Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastro-oesophageal malignancy. Br J Cancer 2006;94:731–736.
13.
Stewart GD, Skipworth RJ, Pennington CJ, Lowrie AG, Deans DA, Edwards DR, Habib FK, Riddick AC, Fearon KC, Ross JA: Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines. Br J Cancer 2008;99:126–132.
14.
Wang Z, Corey E, Hass GM, Higano CS, True LD, Wallace D Jr, Tisdale MJ, Vessella RL: Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer 2003;105:123–129.
15.
Wieland BM, Stewart GD, Skipworth RJ, Sangster K, Fearon KC, Ross JA, Reiman TJ, Easaw J, Mourtzakis M, Kumar V, Pak BJ, Calder K, Filippatos G, Kremastinos DT, Palcic M, Baracos VE: Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res 2007;13:4984–4992.
16.
Monitto CL, Dong SM, Jen J, Sidransky D: Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res 2004;10:5862–5869.
17.
Lee Motoyama JP, Kim-Motoyama H, Kim P, Nakagama H, Miyagawa K, Suzuki K: Identification of dermcidin in human gestational tissue and characterization of its proteolytic activity. Biochem Biophys Res Commun 2007;357:828–833.
18.
Lowrie AG, Wigmore SJ, Wright DJ, Waddell ID, Ross JA: Dermcidin expression in hepatic cells improves survival without N-glycosylation, but requires asparagine residues. Br J Cancer 2006;94:1663–1671.
19.
Stewart GD, Skipworth RJ, Ross JA, Fearon KC, Baracos VE: The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival. Curr Opin Clin Nutr Metab Care 2008;11:208–213.
20.
Toll-Riera M, Laurie S, Rado-Trilla N, Mar Alba M: Partial gene duplication and the formation of novel genes; in Friedberg F (ed): Gene Duplication. InTech 2011, pp 95–110.
21.
McKown RL, Wang N, Raab RW, Karnati R, Zhang Y, Williams PB, Laurie GW: Lacritin and other new proteins of the lacrimal functional unit. Exp Eye Res 2009;88:848–858.
22.
Ma P, Wang N, McKown RL, Raab RW, Laurie GW: Focus on molecules: lacritin. Exp Eye Res 2008;86:457–458.
23.
Waterhouse RM, Zdobnov EM, Tegenfeldt F, Li J, Kriventseva EV: OrthoDB: the hierarchical catalog of eukaryotic orthologs in 2011. Nucleic Acids Res 2011;39:D283–D288.
24.
McDevitt TM, Todorov PT, Beck SA, Khan SH, Tisdale MJ: Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Res 1995;55:1458–1463.
25.
Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M: Characterization of a cancer cachectic factor. Nature 1996;379:739–742.
26.
Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M, Tisdale MJ: Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996;56:1256–1261.
27.
Todorov PT, Wyke SM, Tisdale MJ: Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle. Cancer Res 2007;67:11419–11427.
28.
Hussey HJ, Todorov PT, Field WN, Inagaki N, Tanaka Y, Ishitsuka H, Tisdale MJ: Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor. Br J Cancer 2000;83:56–62.
29.
Mirza KA, Wyke SM, Tisdale MJ: Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF). Br J Cancer 2011;105:83–88.
30.
Cunningham TJ, Jing H, Akerblom I, Morgan R, Fisher TS, Neveu M: Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. Exp Neurol 2002;177:32–39.
31.
Cunningham TJ, Hodge L, Speicher D, Reim D, Tyler-Polsz C, Levitt P, Eagleson K, Kennedy S, Wang Y: Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin. J Neurosci 1998;18:7047–7060.
32.
Dash-Wagh S, Neumann JR, Veitinger S, Grote-Westrick C, Landgraf P, Pape HC, Kreutz MR, von HA, Wahle P: The survival promoting peptide Y-P30 promotes cellular migration. Mol Cell Neurosci 2011;48:195–204.
33.
Landgraf P, Sieg F, Wahle P, Meyer G, Kreutz MR, Pape HC: A maternal blood-borne factor promotes survival of the developing thalamus. FASEB J 2005;19:225–227.
34.
Ambatipudi K, Deane EM: In search of neutrophil granule proteins of the tammar wallaby (Macropus eugenii). Mol Immunol 2008;45:690–700.
35.
Majczak G, Lilla S, Garay-Malpartida M, Markovic J, Medrano FJ, de NG, Belizario JE: Prediction and biochemical characterization of intrinsic disorder in the structure of proteolysis-inducing factor/dermcidin. Genet Mol Res 2007;6:1000–1011.
36.
Baechle D, Flad T, Cansier A, Steffen H, Schittek B, Tolson J, Herrmann T, Dihazi H, Beck A, Mueller GA, Mueller M, Stevanovic S, Garbe C, Mueller CA, Kalbacher H: Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L. J Biol Chem 2006;281:5406–5415.
37.
Flad T, Bogumil R, Tolson J, Schittek B, Garbe C, Deeg M, Mueller CA, Kalbacher H: Detection of dermcidin-derived peptides in sweat by ProteinChip technology. J Immunol Methods 2002;270:53–62.
38.
Sagawa K, Kimura A, Saito Y, Inoue H, Yasuda S, Nosaka M, Tsuji T: Production and characterization of a monoclonal antibody for sweat-specific protein and its application for sweat identification. Int J Legal Med 2003;117:90–95.
39.
Porter D, Weremowicz S, Chin K, Seth P, Keshaviah A, Lahti-Domenici J, Bae YK, Monitto CL, Merlos-Suarez A, Chan J, Hulette CM, Richardson A, Morton CC, Marks J, Duyao M, Hruban R, Gabrielson E, Gelman R, Polyak K: A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci USA 2003;100:10931–10936.
40.
Minami Y, Uede K, Furukawa F, Sagawa K, Kimura A, Tsuji T: Cutaneous mixed tumors: an immunohistochemical study using two antibodies, G-81 and C8/144B. J Dermatol Sci 2004;36:180–182.
41.
Minami Y, Uede K, Sagawa K, Kimura A, Tsuji T, Furukawa F: Immunohistochemical staining of cutaneous tumours with G-81, a monoclonal antibody to dermcidin. Br J Dermatol 2004;151:165–169.
42.
Sakurada K, Akutsu T, Fukushima H, Watanabe K, Yoshino M: Detection of dermcidin for sweat identification by real-time RT-PCR and ELISA. Forensic Sci Int 2010;194:80–84.
43.
Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, Garbe C, Schittek B: Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol 2005;174:8003–8010.
44.
Rieg S, Garbe C, Sauer B, Kalbacher H, Schittek B: Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. Br J Dermatol 2004;151:534–539.
45.
McIntosh RS, Cade JE, Al-Abed M, Shanmuganathan V, Gupta R, Bhan A, Tighe PJ, Dua HS: The spectrum of antimicrobial peptide expression at the ocular surface. Invest Ophthalmol Vis Sci 2005;46:1379–1385.
46.
You J, Fitzgerald A, Cozzi PJ, Zhao Z, Graham P, Russell PJ, Walsh BJ, Willcox M, Zhong L, Wasinger V, Li Y: Post-translation modification of proteins in tears. Electrophoresis 2010;31:1853–1861.
47.
Shaw JL, Smith CR, Diamandis EP: Proteomic analysis of human cervico-vaginal fluid. J Proteome Res 2007;6:2859–2865.
48.
Ghosh R, Karmohapatra SK, Bhattacharyya M, Bhattacharya R, Bhattacharya G, Sinha AK: The appearance of dermcidin isoform 2, a novel platelet aggregating agent in the circulation in acute myocardial infarction that inhibits insulin synthesis and the restoration by acetyl salicylic acid of its effects. J Thromb Thrombolysis 2011;31:13–21.
49.
Lominadze G, Powell DW, Luerman GC, Link AJ, Ward RA, McLeish KR: Proteomic analysis of human neutrophil granules. Mol Cell Proteomics 2005;4:1503–1521.
50.
Todorov PT, Field WN, Tisdale MJ: Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer 1999;80:1734–1737.
51.
Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ: Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997;76:606–613.
52.
Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC: Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000;87:53–58.
53.
Cabal-Manzano R, Bhargava P, Torres- Duarte A, Marshall J, Bhargava P, Wainer IW: Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 2001;84:1599–1601.
54.
Teich N, Kleeff J, Lochs H, Mossner J, Keim V, Friess H, Ockenga J: The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterol 2005;5:20.
55.
Jatoi A, Foster N, Wieland B, Murphy B, Nikcevich D, LaPlant B, Palcic MM, Baracos V: The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. Dis Esophagus 2006;19:241–247.
56.
Helms MW, Packeisen J, August C, Schittek B, Boecker W, Brandt BH, Buerger H: First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 2005;206:366–376.
57.
Shen SL, Qiu FH, Dayarathna TK, Wu J, Kuang M, Li SS, Peng BG, Nie J: Identification of dermcidin as a novel binding protein of Nck1 and characterization of its role in promoting cell migration. Biochim Biophys Acta 2011;1812:703–710.
58.
Stocki P, Wang XN, Morris NJ, Dickinson AM: HSP70 natively and specifically associates with an N-terminal dermcidin-derived peptide that contains an HLA-A*03 antigenic epitope. J Biol Chem 2011;286:12803–12811.
59.
Pathak S, De Souza GA, Salte T, Wiker HG, Asjo B: HIV induces both a down-regulation of IRAK-4 that impairs TLR signalling and an up-regulation of the antibiotic peptide dermcidin in monocytic cells. Scand J Immunol 2009;70:264–276.
60.
Cunningham TJ, Jing H, Wang Y, Hodge L: Calreticulin binding and other biological activities of survival peptide Y-P30 including effects of systemic treatment of rats. Exp Neurol 2000;163:457–468.
61.
Lowrie AG, Dickinson P, Wheelhouse N, Stewart GD, Ross AJ, Forster T, Ross JA: Proteolysis-inducing factor core peptide mediates dermcidin-induced proliferation of hepatic cells through multiple signalling networks. Int J Oncol 2011;39:709–718.
62.
Stewart GD, Lowrie AG, Riddick AC, Fearon KC, Habib FK, Ross JA: Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia. Prostate 2007;67:1308–1317.
63.
Macharadze T, Landgraf P, Pape HC, Wahle P, Kreutz MR: Y-P30 confers neuroprotection after optic nerve crush in adult rats. Neuroreport 2011;22:544–547.
64.
Landgraf P, Wahle P, Pape HC, Gundelfinger ED, Kreutz MR: The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity. J Biol Chem 2008;283:25036–25045.
65.
Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ: Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 2001;85:297–302.
66.
Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ: Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 1998;78:850–856.
67.
Watchorn TM, Waddell I, Dowidar N, Ross JA: Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-ĸB and STAT3. FASEB J 2001;15:562–564.
68.
Todorov PT, Deacon M, Tisdale MJ: Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 1997;272:12279–12288.
69.
Lorite MJ, Cariuk P, Tisdale MJ: Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997;76:1035–1040.
70.
Whitehouse AS, Tisdale MJ: Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-ĸB. Br J Cancer 2003;89:1116–1122.
71.
Kim KA, Ka SO, Moon WS, Yi HK, Lee YH, Kwon KB, Park JW, Park BH: Effect of dermcidin, an antimicrobial peptide, on body fat mobilization in normal mice. J Endocrinol 2008;198:111–118.
72.
Senyurek I, Paulmann M, Sinnberg T, Kalbacher H, Deeg M, Gutsmann T, Hermes M, Kohler T, Gotz F, Wolz C, Peschel A, Schittek B: Dermcidin-derived peptides show a different mode of action than the cathelicidin LL-37 against Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:2499–2509.
73.
Lai YP, Peng YF, Zuo Y, Li J, Huang J, Wang LF, Wu ZR: Functional and structural characterization of recombinant dermcidin-1L, a human antimicrobial peptide. Biochem Biophys Res Commun 2005;328:243–250.
74.
Li M, Rigby K, Lai Y, Nair V, Peschel A, Schittek B, Otto M: Staphylococcus aureus mutant screen reveals interaction of the human antimicrobial peptide dermcidin with membrane phospholipids. Antimicrob Agents Chemother 2009;53:4200–4210.
75.
Cipakova I, Gasperik J, Hostinova E: Expression and purification of human antimicrobial peptide, dermcidin, in Escherichia coli. Protein Expr Purif 2006;45:269–274.
76.
Vuong C, Voyich JM, Fischer ER, Braughton KR, Whitney AR, DeLeo FR, Otto M: Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell Microbiol 2004;6:269–275.
77.
Steffen H, Rieg S, Wiedemann I, Kalbacher H, Deeg M, Sahl HG, Peschel A, Gotz F, Garbe C, Schittek B: Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob Agents Chemother 2006;50:2608–2620.
78.
Hong I, Kim YS, Choi SG: Simple purification of human antimicrobial peptide dermcidin (MDCD-1L) by intein-mediated expression in E. coli. J Microbiol Biotechnol 2010;20:350–355.
79.
Jung HH, Yang ST, Sim JY, Lee S, Lee JY, Kim HH, Shin SY, Kim JI: Analysis of the solution structure of the human antibiotic peptide dermcidin and its interaction with phospholipid vesicles. BMB Rep 2010;43:362–368.
80.
Paulmann M, Arnold T, Linke D, Ozdirekcan S, Kopp A, Gutsmann T, Kalbacher H, Wanke I, Schuenemann VJ, Habeck M, Burck J, Ulrich AS, Schittek B: Structure-activity analysis of the dermcidin-derived peptide DCD 1L, an anionic antimicrobial peptide present in human sweat. J Biol Chem 2012;287:8434–8443.
81.
Senyurek I, Doring G, Kalbacher H, Deeg M, Peschel A, Wolz C, Schittek B: Resistance to dermcidin-derived peptides is independent of bacterial protease activity. Int J Antimicrob Agents 2009;34:86–90.
82.
Lai Y, Villaruz AE, Li M, Cha DJ, Sturdevant DE, Otto M: The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in staphylococci. Mol Microbiol 2007;63:497–506.
83.
Li M, Lai Y, Villaruz AE, Cha DJ, Sturdevant DE, Otto M: Gram-positive three-component antimicrobial peptide-sensing system. Proc Natl Acad Sci USA 2007;104:9469–9474.
84.
Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M: The antimicrobial peptide-sensing system APS of Staphylococcus aureus. Mol Microbiol 2007;66:1136–1147.
85.
Niyonsaba F, Suzuki A, Ushio H, Nagaoka I, Ogawa H, Okumura K: The human antimicrobial peptide dermcidin activates normal human keratinocytes. Br J Dermatol 2009;160:243–249.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.